Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest update is out from Otsuka Holdings Co ( (JP:4578) ).
Otsuka Holdings has announced promising interim results from its Phase 3 VISIONARY study, showing that its investigational drug sibeprenlimab achieved a significant 51.2% reduction in proteinuria for patients with Immunoglobulin A Nephropathy (IgAN). The study’s findings, presented at the European Renal Association Congress, highlight sibeprenlimab’s potential as a new treatment option, with a favorable safety profile and a novel mechanism targeting the disease’s immunologic pathogenesis. The drug has received Priority Review from the FDA, indicating its potential impact on the treatment landscape for this chronic kidney disease.
The most recent analyst rating on (JP:4578) stock is a Hold with a Yen7200.00 price target. To see the full list of analyst forecasts on Otsuka Holdings Co stock, see the JP:4578 Stock Forecast page.
More about Otsuka Holdings Co
Otsuka Holdings Co., Ltd. operates in the pharmaceutical industry, focusing on the development and commercialization of innovative medical products. The company is known for its work in various therapeutic areas, including nephrology, and aims to address unmet medical needs with a strong emphasis on research and development.
Average Trading Volume: 1,353,972
Technical Sentiment Signal: Buy
Current Market Cap: Yen3665.4B
See more insights into 4578 stock on TipRanks’ Stock Analysis page.